KSKran Suknuntha

Kran Suknuntha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kran Suknuntha has a total of 152 co-authors. Here are the top co-authors by number of shared publications:

  • Igor I. Slukvin

    Wisconsin National Primate Research Center, University of Wisconsin, Madison, WI 53715, USA

    9 shared publications
  • Ron Stewart

    Morgridge Institute for Research, Madison, WI 53707, United States

    4 shared publications
  • Akhilesh Kumar

    Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA

    3 shared publications
  • Igor Slukvin

    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, United States

    3 shared publications
  • James A. Thomson

    Morgridge Institute for Research, 330 N. Orchard Street, Madison, WI 53715, USA; Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53707-7365, USA; Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA

    3 shared publications
  • Kyung-Dal Choi

    Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, MN, USA

    3 shared publications

Latest Publications

  • Open Access

    Generation of osteoclast-like cells from human peripheral blood mononuclear cells using NFATc1 modified RNA

    by Sirada Srihirun, Chareerut Phruksaniyom, Thanaporn Sriwantana, Tipparat Parakaw, Nathawut Sibmooh, Pornpun Vivithanaporn, Kran Suknuntha

    Inhibition of osteoclasts, a type of bone-resorptive cell, is a key approach for treating diseases associated with bone loss. Although human osteoclasts can be generated from receptor activator of nuclear factor-ĸB ligand-mediated stimulation of peripheral blood mononuclear cells (PBMCs) in vitro, the differentiation rate is low and the process is time consuming. Here, we aimed to generate osteoclast-like cells from human PBMCs using modified RNA (modRNA) enforcing NFATc1 , a master transcription factor that functions downstream of receptor activator of nuclear factor-ĸB receptor activation. Human PBMCs isolated from the venous blood of healthy donors (n = 3) using Histopaque density gradient centrifugation were expanded in medium supplemented with 25 ng/mL macrophage colony-stimulating factor for 3 days. The isolated macrophages were transfected with NFATc1 modRNA. The osteoclast-like cells were evaluated for the following osteoclast-specific markers: tartrate-resistant acid phosphatase-positive expression, F-actin ring formation, cathepsin expression, and bone resorption activity. Scanning electron microscopy was used to morphologically characterize the osteoclast-like cells. At day 1 posttransfection with 25, 50, and 100 ng/mL of modRNA, NFATc1 expression in human macrophages increased by 1.20 ± 0.08-fold, 3.47 ± 1.02-fold, and 13.31 ± 3.96-fold, respectively. Transfection with 25 or 50 ng/mL of NFATc1 modRNA for 3 days induced the formation of tartrate-resistant acid phosphatase-positive multinucleated cells, the F-actin ring formation, expression of cathepsin K, and increased bone resorption activity. Scanning electron micrographs confirmed the presence of round, multinucleated cells with projecting microvilli, characteristic of osteoclasts. In conclusion, rapid generation of functional osteoclast-like cells was achieved in vitro using NFATc1 modRNA. This method offers faster results compared with conventional receptor activator of nuclear factor-ĸB ligand stimulation.


  • Open Access

    Transcriptome analysis reveals a role of FOXO3 in antileukemia/lymphoma properties of panduratin A

    by Suttinee Phuagkhaopong, Jiranan Janpattanapichai, Noppavut Sirirak, Phisit Khemawoot, Pornpun Vivithanaporn, Kran Suknuntha

    Boesenbergia rotunda, commonly known as fingerroot, is a medicinal and culinary plant native to the Indochina Peninsula. We found that panduratin A (Pan-A), one of the compounds present in the rhizome extract of fingerroot, inhibited cell proliferation, induced apoptosis, and promoted cell cycle arrest at G0/G1 phase in multiple hematologic malignant cell lines including leukemia and lymphoma lines. Pan-A inhibited these activities in leukemia and lymphoma cells in a concentration-dependent manner. High-throughput transcriptome analysis indicated that Pan-A is involved in the cell cycle, cellular senescence, apoptosis, and multiple canonical signaling pathways in lymphoma cells. The Forkhead box O (FOXO) transcription factor family was identified as a potential target of Pan-A. Western blot showed elevated caspase 7 and cPARP/PARP in the B-cell lymphoma cells after treatment with Pan-A. The inhibitory effects were accompanied by stimulation of Akt signaling and phosphorylation of FOXO3. Immunohistochemistry of tissues from patients with B-cell lymphoma revealed detectable levels of FOXO3 protein specifically in neoplastic B cells. Overall, our results highlight FOXO3 as a player underlying antileukemia/lymphoma effects of Pan-A.


  • Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation

    by Kran Suknuntha, Julia T. Geyer, Keyur Pravinchandra Patel, Olga K. Weinberg, Heesun J. Rogers, Jonathan I. Lake, Luke Lauridsen, Jay L. Patel, Michael J. Kluk, Daniel A. Arber, et al.


  • Open Access

    Plasmapheresis for Thrombotic Microangiopathy Due to a Post-transplant Lymphoproliferative Disorder

    by Qiqi Yu, Kran Suknuntha, Weixiong Zhong, Daniel R. Matson, Aaron S. Hess, William N. Rose

    We report a case of thrombotic microangiopathy (TMA) diagnosed in the kidney allograft of a 59-year-old woman who had developed plasmacytoma type monomorphic posttransplant lymphoproliferative disorder (PTLD) 30 years after a simultaneous pancreas and kidney transplant. This report demonstrates a rare etiology of TMA in a kidney allograft occurring in association with PTLD-associated monoclonal gammopathy. The main teaching points are: 1) PTLD may be considered in the work-up of a new TMA in the immunosuppressed post-transplant setting, and 2) a paraprotein-associated condition should be considered as clinically relevant coexistent in a patient with TMA because paraproteins are over-represented in patients with otherwise unexplained TMAs.

  • Open Access

    MHC-matched allogeneic bone marrow transplants fail to eliminate SHIV-infected cells from ART-suppressed Mauritian cynomolgus macaques

    by Jason T. Weinfurter, Saritha S. D’souza, Lea M. Matschke, Sarah Bennett, Laurel E. Kelnhofer-Millevolte, Kran Suknuntha, Akhilesh Kumar, Jennifer Coonen, Christian M. Capitini, Peiman Hematti, et al.

    Background: Allogeneic hematopoietic stem cell transplants (allo-HSCTs) dramatically reduce HIV reservoirs in antiretroviral therapy (ART) suppressed individuals. However, the mechanism(s) responsible for these post-transplant viral reservoir declines are not fully understood but may include pre-transplant conditioning regimens, ART-mediated protection of donor cells, and graft-versus-host (GvH) responses. Therefore, we modeled allo-HSCT in ART-suppressed simian-human immunodeficiency virus (SHIV)-infected Mauritian cynomolgus macaques (MCMs) to illuminate factors contributing to transplant-induced viral reservoir decay. Results: We infected four MCMs with CCR5-tropic SHIV162P3 and started ART 6-16 weeks post-infection (p.i.) to establish robust viral reservoirs. We maintained the MCMs on continuous ART during myeloablative conditioning with total body irradiation (TBI) and while transplanting allogeneic MHC-matched α/β T cell-depleted bone marrow cells. Post-transplant, we prophylactically treated the MCMs with cyclophosphamide and tacrolimus to prevent GvH disease (GvHD). The transplants produced ~85% whole blood donor chimerism without causing high-grade GvHD. Consequently, three MCMs had undetectable SHIV DNA in their peripheral blood mononuclear cells post-transplant. However, SHIV-harboring cells persisted in various tissues. We detected viral DNA in lymph node biopsies and terminal analyses of tissues between 38 and 62 days post-transplant. Further, we removed ART from one MCM at 63 days post-transplant, resulting in viral rebound within seven days and viral loads nearing 1×10 8 SHIV RNA copies/ml of plasma after treatment interruption. Conclusions: Our results indicate that myeloablative conditioning and maintaining ART through the peri-transplant period alone are insufficient for eradicating latent viral reservoirs early after allo-HSCTs. Furthermore, our findings suggest that extended ART and GvH responses may be necessary to substantially deplete viral reservoirs after allo-HSCTs.

  • Open Access

    SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis

    by Ho Sun Jung, Gene Uenishi, Mi Ae Park, Peng Liu, Kran Suknuntha, Matthew Raymond, Yoon Jung Choi, James A. Thomson, Irene M. Ong, Igor I. Slukvin


  • Open Access

    Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition

    by Kran Suknuntha, Yoon Jung Choi, Ho Sun Jung, Aditi Majumder, Sujal Shah, Igor Slukvin, Erik A. Ranheim

    Numerous recurrent genetic mutations are known to occur in acute myeloid leukemia (AML). Among these common mutations, Fms-like tyrosine kinase 3 remains as one of the most frequently mutated genes in AML. We observed apparent marrow expansion of megakaryocytes in three out of six patients with Flt3-mutated AML following treatment with a recently FDA-approved Flt3 inhibitor, gilteritinib which possesses activity against internal tandem duplication and tyrosine kinase domain Flt3 mutations and also inhibits tyrosine kinase AXL. To assess whether biopsy findings can be attributed to promotion of megakaryocytic (Mk) differentiation with gilteritinib, we devised a cellular assay by overexpressing double mutated Flt3-ITDY591F/Y919F in chronic myeloid leukemia cell line K562 to study Mk differentiation in the presence of Flt3 and AXL inhibitors with non-mutually exclusive mechanisms. These experiments demonstrated the lack of direct effect Flt3 inhibitors gilteritinib and quizartinib on megakaryocytic differentiation at either transcriptional or phenotypic levels, and highlighted antileukemic effects of AXL receptor tyrosine kinase inhibitor and its potential role in megakaryocytic development.


  • Transplantation of T-cell receptor α/β-depleted allogeneic bone marrow in nonhuman primates

    by Saritha S. D'SOuza, Sarah Bennett, Akhilesh Kumar, Laurel E. Kelnhofer, Jason Weinfurter, Kran Suknuntha, Jennifer Coonen, Andres Mejia, Heather Simmons, Thaddeus Golos, et al.


  • Open Access

    UM171 expands distinct types of myeloid and NK progenitors from human pluripotent stem cells

    by Walatta-Tseyon Mesquitta, Matthew Wandsnider, HyunJun Kang, James Thomson, Oleg Moskvin, Kran Suknuntha, Igor I. Slukvin

    Scaling up blood cell production from hPSCs is critical to advancing hPSC technologies for blood transfusion, immunotherapy, and transplantation. Here we explored the potential of the HSC agonist pyrimido-indole derivative UM171, to expand hematopoietic progenitors (HPs) derived from hPSCs in chemically defined conditions. We revealed that culture of hPSC-HPs in HSC expansion conditions (SFEM with added TPO, SCF, FLT3L, IL3 and IL6) in the presence of UM171 predominantly expanded HPs with a unique CD34+CD41aloCD45+ phenotype that were enriched in granulocytic progenitors (G-CFCs). In contrast, in lymphoid cultures on OP9-DLL4, in the presence of SCF, FLT3L, and IL7, UM171 selectively expanded CD34+CD45+CD7+ lymphoid progenitors with NK cell potential, and increased NK cell output up to 10-fold. These studies should improve our understanding of the effect of UM171 on de novo generated HPs, and facilitate development of protocols for robust granulocyte and lymphoid cell production from hPSCs, for adoptive immunotherapies.